Smith & Nephew (SNN) is down about 3% in U.S. trading as investors reprice the company’s 2026 outlook and execution risk. The latest selloff lines up with ongoing concerns that this year’s guidance could prove fragile as acquisition-related costs and reimbursement pressures hit earnings power.

Smith & Nephew has said 2026 should bring accelerating underlying revenue growth of around 6%, but it also flagged that the recently completed Integrity Orthopaedics acquisition is expected to be marginally dilutive to trading profit in 2026, turning broadly neutral in 2027 and accretive in 2028. Including that dilution, the company targets trading profit of around $1.3 billion and free cash flow around $800 million, leaving the market sensitive to any sign that integration costs or demand trends could push results below the bar.

In Advanced Wound Management, the company has pointed to softness in skin substitutes ahead of reimbursement changes in 2026, an issue that has already been influencing business mix and investor expectations. With reimbursement still a key swing factor for the wound bioactives portfolio, traders are treating the segment as a near-term risk to margins and growth as 2026 unfolds.

The next major read-through is the company’s upcoming earnings/trading updates, where investors will look for confirmation that 2026 revenue momentum is holding and that integration and reimbursement impacts remain consistent with prior framing. Any changes to the expected profit cadence, cost savings delivery, or wound-care trajectory are likely to drive outsized moves given the stock’s sensitivity to guidance credibility.